Insider Selling: Becton, Dickinson and Company (NYSE:BDX) EVP Sells $11,051.25 in Stock

30 May 2026, 07:38 by Amy Steele · The Cerbat Gem

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) EVP Michael Feld sold 75 shares of the stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $147.35, for a total transaction of $11,051.25. Following the completion of the sale, the executive vice president directly owned 21,084 shares in the company, valued at approximately $3,106,727.40. This represents a 0.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Feld also recently made the following trade(s):

On Monday, April 27th, Michael Feld sold 74 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $151.94, for a total transaction of $11,243.56.
On Thursday, February 26th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $181.84, for a total transaction of $13,638.00.

Becton, Dickinson and Company Trading Down 0.9%

Shares of BDX opened at $147.13 on Friday. The company’s fifty day simple moving average is $151.63 and its 200-day simple moving average is $177.02. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The company has a market cap of $40.54 billion, a P/E ratio of 37.25, a P/E/G ratio of 10.51 and a beta of 0.22. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, topping the consensus estimate of $2.77 by $0.13. The company had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.67 billion. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The firm’s revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the firm posted $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, analysts expect that Becton, Dickinson and Company will post 12.61 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be paid a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 106.33%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on BDX. Citigroup lowered their price target on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating for the company in a report on Tuesday, February 10th. Wells Fargo & Company boosted their price target on Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an “equal weight” rating in a report on Friday, May 8th. JPMorgan Chase & Co. lowered their price target on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating for the company in a report on Tuesday, February 10th. Barclays boosted their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Finally, TD Cowen lowered their price target on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating for the company in a report on Monday, May 4th. Seven investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $183.64.

Get Our Latest Stock Report on Becton, Dickinson and Company

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Activest Wealth Management increased its position in Becton, Dickinson and Company by 285.3% during the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 97 shares during the period. Imprint Wealth LLC purchased a new position in Becton, Dickinson and Company during the 3rd quarter valued at about $25,000. Steph & Co. increased its position in Becton, Dickinson and Company by 95.6% during the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 65 shares during the period. SHP Wealth Management purchased a new position in Becton, Dickinson and Company during the 4th quarter valued at about $26,000. Finally, Prosperity Bancshares Inc purchased a new position in Becton, Dickinson and Company during the 4th quarter valued at about $29,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

(Get Free Report)

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.